In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews, December 2014

Executive Summary

This Month's Profile Group: Closing In On An Artificial Pancreas, features profiles of Beta-O2, Defymed, and Pancreum. Plus these Start-Ups Across Health Care: Biogelx, COTA, Kesios Therapeutics, and OtoKinetics.

You may also be interested in...

OtoKinetics Inc.

Currently, people with severe hearing loss are treated with conventional hearing aids, which have less than a 50% success rate due to such problems as feedback and discomfort. OtoKinetics Inc. hopes to increase that efficacy rate to at least 90% with its Krescendo implant, a titanium device about the size of a grain of rice that is inserted into the cochlea.

Closing In On An Artificial Pancreas

Medtronic may be the front-runner in the race to market, but a number of medtech start-ups hope investors will find merit in their innovative technologies. Profiles of Beta-O2, Defymed, and Pancreum.

Defymed Inc.

Defymed Inc.’s MAILPAN (MAcro-encapsulation of PANcreatic Islets) is a bioartificial pancreas that can use a broader pool of cell types while protecting the cells from rejection by the immune system.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts